Meeting
2020 Genitourinary Cancers Symposium
Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Authors
Jonathan E. Rosenberg
Memorial Sloan Kettering Cancer Center, New York, NY
Jonathan E. Rosenberg , Thomas W. Flaig , Terence W. Friedlander , Matthew I. Milowsky , Sandy Srinivas , Daniel Peter Petrylak , Jaime R. Merchan , Mehmet Asim Bilen , Anne-Sophie Carret , Nancy Yuan , Carolyn Sasse , Christopher J. Hoimes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03288545
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 441)
Abstract #
441
Poster Bd #
A4
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
First Author: Jonathan E. Rosenberg
Poster
2020 ASCO Virtual Scientific Program
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
First Author: Nataliya Mar
Poster
2021 ASCO Annual Meeting
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
First Author: Terence W. Friedlander
Poster
2023 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
First Author: Peter H. O'Donnell